Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice

Chronic liver disease results in a low response rate to the hepatitis B virus vaccine. Information on the efficacy of the double adjuvanted vaccine FENDRIX(®) (3-O-desacyl-4’-monophosphoryl lipid A and aluminum phosphate) and single adjuvant HBVAXPRO(®)40 (aluminum hydroxyphosphate sulfate) in chron...

Descripción completa

Detalles Bibliográficos
Autores principales: Horta, Diana, Forné, Montserrat, Agustí, Anna, Raga, Agnes, Martín-Cardona, Albert, Hernández-Soto, Juana María, Ruiz-Ramírez, Pablo, Esteve-Comas, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416157/
https://www.ncbi.nlm.nih.gov/pubmed/36016211
http://dx.doi.org/10.3390/vaccines10081323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416157/
https://www.ncbi.nlm.nih.gov/pubmed/36016211
http://dx.doi.org/10.3390/vaccines10081323

Ejemplares similares